Envoy Medical Inc (COCH)

$2.75

+0.02

(+0.73%)▲

Live

Performance

  • $2.71
    $2.80
    $2.75
    downward going graph

    1.45%

    Downside

    Day's Volatility :3.21%

    Upside

    1.79%

    downward going graph
  • $0.75
    $11.46
    $2.75
    downward going graph

    72.83%

    Downside

    52 Weeks Volatility :93.48%

    Upside

    76.0%

    downward going graph

Returns

PeriodEnvoy Medical IncIndex (Russel 2000)
3 Months
22.22%
0.0%
6 Months
-45.44%
0.0%
1 Year
77.42%
0.0%
3 Years
-71.79%
-23.0%

Highlights

Market Capitalization
54.1M
Book Value
-$0.63
Earnings Per Share (EPS)
-0.83
Wall Street Target Price
5.94
Profit Margin
0.0%
Operating Margin TTM
-7147.06%
Return On Assets TTM
-266.32%
Return On Equity TTM
0.0%
Revenue TTM
302.0K
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
7.9%
Gross Profit TTM
-720.0K
EBITDA
-19.7M
Diluted Eps TTM
-0.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.07
EPS Estimate Next Year
-1.12
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Envoy Medical Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 116.0%

Current $2.75
Target $5.94

Company Financials

FY21Y/Y Change
Revenue
310.0K
-
Net Income
-8.7M
↑ 1237417.83%
Net Profit Margin
-2.8K%
-
FY22Y/Y Change
Revenue
237.0K
↓ 23.55%
Net Income
-15.9M
↑ 83.55%
Net Profit Margin
-6.7K%
↓ 3920.18%
FY23Y/Y Change
Revenue
316.0K
↑ 33.33%
Net Income
-29.9M
↑ 87.83%
Net Profit Margin
-9.5K%
↓ 2745.99%
Q1 FY23Q/Q Change
Revenue
78.0K
↑ 290.0%
Net Income
717.7K
↓ 106.25%
Net Profit Margin
920.13%
↑ 58305.13%
Q2 FY23Q/Q Change
Revenue
63.0K
↓ 19.23%
Net Income
-13.2M
↓ 1945.62%
Net Profit Margin
-21.0K%
↓ 21945.53%
Q3 FY23Q/Q Change
Revenue
80.0K
↑ 26.98%
Net Income
1.6M
↓ 111.8%
Net Profit Margin
2.0K%
↑ 22979.15%
Q4 FY23Q/Q Change
Revenue
95.0K
↑ 18.75%
Net Income
-4.9M
↓ 412.28%
Net Profit Margin
-5.1K%
↓ 7091.64%
Q1 FY24Q/Q Change
Revenue
59.0K
↓ 37.89%
Net Income
-6.3M
↑ 28.46%
Net Profit Margin
-10.6K%
↓ 5489.23%
Q2 FY24Q/Q Change
Revenue
68.0K
↑ 15.25%
Net Income
-3.9M
↓ 37.05%
Net Profit Margin
-5.8K%
↑ 4822.71%
FY20Y/Y Change
Total Assets
120.0K
-
Total Liabilities
95.7K
-
FY21Y/Y Change
Total Assets
2.6M
↑ 2086.81%
Total Liabilities
47.6M
↑ 49625.69%
FY22Y/Y Change
Total Assets
2.6M
↓ 2.59%
Total Liabilities
58.7M
↑ 23.41%
FY23Y/Y Change
Total Assets
7.6M
↑ 198.9%
Total Liabilities
9.4M
↓ 83.99%
Q1 FY23Q/Q Change
Total Assets
45.9M
↑ 1696.61%
Total Liabilities
21.0M
↓ 64.28%
Q2 FY23Q/Q Change
Total Assets
2.6M
↓ 94.35%
Total Liabilities
82.3M
↑ 292.18%
Q3 FY23Q/Q Change
Total Assets
23.6M
↑ 810.18%
Total Liabilities
17.3M
↓ 78.92%
Q4 FY23Q/Q Change
Total Assets
7.6M
↓ 67.63%
Total Liabilities
9.4M
↓ 45.78%
Q1 FY24Q/Q Change
Total Assets
8.5M
↑ 10.99%
Total Liabilities
15.9M
↑ 69.04%
Q2 FY24Q/Q Change
Total Assets
6.7M
↓ 20.55%
Total Liabilities
19.1M
↑ 20.33%
FY21Y/Y Change
Operating Cash Flow
-6.9M
-
Investing Cash Flow
-125.0K
-
Financing Cash Flow
8.1M
-
FY22Y/Y Change
Operating Cash Flow
-8.8M
↑ 26.95%
Investing Cash Flow
-218.0K
↑ 74.4%
Financing Cash Flow
8.1M
↑ 0.42%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.2M
↓ 8.38%
Investing Cash Flow
-59.0K
-
Financing Cash Flow
4.0M
↑ 100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-678.9K
↓ 68.85%
Investing Cash Flow
-11.0K
↓ 81.36%
Financing Cash Flow
3.0M
↓ 25.0%

Technicals Summary

Sell

Neutral

Buy

Envoy Medical Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Envoy Medical Inc
Envoy Medical Inc
-26.08%
-45.44%
77.42%
-71.79%
-71.41%
Stryker Corporation
Stryker Corporation
0.83%
12.78%
40.21%
33.69%
71.83%
Boston Scientific Corp.
Boston Scientific Corp.
4.85%
29.48%
75.68%
96.28%
127.87%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
4.32%
-19.19%
1.77%
-39.29%
-7.22%
Abbott Laboratories
Abbott Laboratories
3.99%
11.51%
24.65%
-4.53%
46.22%
Medtronic Plc
Medtronic Plc
2.65%
14.48%
27.42%
-24.18%
-13.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Envoy Medical Inc
Envoy Medical Inc
NA
NA
NA
-1.07
0.0
-2.66
NA
-0.63
Stryker Corporation
Stryker Corporation
40.15
40.15
2.64
12.01
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
70.26
70.26
2.14
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.67
27.67
3.65
2.6
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.83
35.83
4.31
4.67
0.14
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
30.23
30.23
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Envoy Medical Inc
Envoy Medical Inc
Buy
$54.1M
-71.41%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$137.1B
71.83%
40.15
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$127.3B
127.87%
70.26
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.3B
-7.22%
27.67
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$205.1B
46.22%
35.83
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.2B
-13.49%
30.23
12.06%

Insights on Envoy Medical Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 59.0K → 68.0K (in $), with an average increase of 13.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.27M → -3.94M (in $), with an average increase of 58.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 11.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 168.0%

Company Information

Organization
Envoy Medical Inc
Employees
34
CEO
Mr. Brent T. Lucas Esq.
Industry
Miscellaneous

Discover More

FAQs